1211.HK
002594.SHE

A subcontractor building a Brazilian factory for leading Chinese new energy vehicle (NEV) maker BYD Co. Ltd. (1211.HK; 002594.SZ) has been accused of serious labor rights at its construction site in Camaçari, Bahia, Brazil’s Ministry of Labor and Employment said on Monday. Media reports indicated that 163 workers were living in harsh conditions at the site.

The 163 workers were employed by China Jinjiang Construction Brazil Ltd., which provides services to BYD on an outsourced basis, financial media Caixin reported on Tuesday. Worker dormitories and parts of the construction site have since been shut down and operations suspended.

BYD told Caixin that the subcontractor failed to meet BYD’s labor standards, leading to an immediate termination of their partnership. BYD’s Brazil division also affirmed its commitment to safeguarding all rights of the subcontracted workers.

BYD has been expanding in Brazil in recent years. In July 2023, it announced a 3 billion real ($472 million) investment to build three factories in Camaçari. To date, BYD has launched 13 NEV models in the region. As of Dec. 13, BYD has sold about 70,000 NEVs in Brazil, up 290% from 2023.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…